{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:13:37Z","timestamp":1792466017538,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/ja.2014.106","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T08:04:50Z","timestamp":1407312290000},"page":"667-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Rifaximin: beyond the traditional antibiotic activity"],"prefix":"10.1038","volume":"67","author":[{"given":"Fiorella","family":"Calanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Claudio","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"BFja2014106_CR1","first-page":"262","volume":"7","author":"P Sensi","year":"1959","unstructured":"Sensi, P., Greco, A. M. & Ballotta, R. Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot. Ann. 7, 262\u2013270 (1959-1960).","journal-title":"Antibiot. Ann."},{"key":"BFja2014106_CR2","unstructured":"Marchi, E. & Montecchi, L. Imidazo-Rifamycin derivatives with antibacterial utility. US Patent 4341785 (1982)."},{"key":"BFja2014106_CR3","unstructured":"Cannata, V. & Tamagnone, G. F. Process for the synthesis of pyrido-imidazo Rifamycins. US patent 4557866 (1985)."},{"issue":"suppl 1","key":"BFja2014106_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000081991","volume":"51","author":"ZD Jiang","year":"2005","unstructured":"Jiang, Z. D. & DuPont, H. L. Rifaximin: in vitro and in vivo. Antibacterial activity\u2013a review. Chemotherapy 51 (suppl 1), 67\u201372 (2005).","journal-title":"Chemotherapy"},{"key":"BFja2014106_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","volume":"49","author":"JC Gillis","year":"1995","unstructured":"Gillis, J. C. & Brogden, R. N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49, 467\u2013484 (1995).","journal-title":"Drugs"},{"key":"BFja2014106_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1039\/b717887e","volume":"10","author":"GC Viscomi","year":"2008","unstructured":"Viscomi, G. C. et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. Cryst. Eng. Comm. 10, 1074\u20131081 (2008).","journal-title":"Cryst. Eng. Comm."},{"key":"BFja2014106_CR7","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang, Z. D., Ke, S., Palazzini, E., Riopel, L. & Dupont, H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44, 2205\u20132206 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR8","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1128\/AAC.00161-10","volume":"54","author":"C Darkoh","year":"2010","unstructured":"Darkoh, C. et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob. Agents Chemother. 54, 3618\u20133624 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","volume":"142","author":"C Prantera","year":"2012","unstructured":"Prantera, C. et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 142, 473\u2013481 (2012).","journal-title":"Gastroenterology"},{"key":"BFja2014106_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1128\/AAC.45.1.212-216.2001","volume":"45","author":"H Gomi","year":"2001","unstructured":"Gomi, H. et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler\u2019s diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45, 212\u2013216 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","volume":"35","author":"ZD Jiang","year":"2010","unstructured":"Jiang, Z. D., Ke, S. & DuPont, H. L. Rifaximin-induced alteration of virulence of diarrhea-producing Escherichia coli and Shigella sonnei. Int. J. Antimicrob. Agents 35, 278\u2013281 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2014106_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1179\/joc.2008.20.2.186","volume":"20","author":"E Debbia","year":"2008","unstructured":"Debbia, E., Maioli, E., Roveta, S. & Marchese, A. Effect of rifaximin on bacterial virulence mechanism at supra- and subinhibitory concentrations. J Chemother. 20, 186\u2013194 (2008).","journal-title":"J Chemother."},{"key":"BFja2014106_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.00691-09","volume":"54","author":"EL Brown","year":"2010","unstructured":"Brown, E. L. et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother. 54, 388\u2013396 (2010).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFja2014106_CR14","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1086\/323814","volume":"33","author":"HL Dupont","year":"2001","unstructured":"Dupont, H. L. et al. Rifaximin versus ciprofloxacin for the treatment of travelers\u2019 diarrhea: a randomized, double-blind clinical trial. Clin. Infec. Dis. 33, 1807\u20131815 (2001).","journal-title":"Clin. Infec. Dis."},{"key":"BFja2014106_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.4269\/ajtmh.2006.74.1060","volume":"74","author":"DN Taylor","year":"2006","unstructured":"Taylor, D. N. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am. J. Trop. Med. Hyg. 74, 1060\u20131066 (2006).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"BFja2014106_CR16","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","volume":"65","author":"S Maccaferri","year":"2010","unstructured":"Maccaferri, S. et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J. Antimicrob. Chemother. 65, 2556\u20132565 (2010).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFja2014106_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000007297","volume":"46","author":"A Marchese","year":"2000","unstructured":"Marchese, A., Salerno, A., Pesce, A., Debbia, E. A. & Schito, G. C. In vitro activity of Rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46, 253\u2013266 (2000).","journal-title":"Chemotherapy"},{"key":"BFja2014106_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/14656566.2011.546347","volume":"12","author":"HL DuPont","year":"2011","unstructured":"DuPont, H. L. Biologic properties and clinical uses of rifaximin. Expert. Opin. Pharmacother. 12, 293\u2013302 (2011).","journal-title":"Expert. Opin. Pharmacother."},{"key":"BFja2014106_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1128\/AAC.45.2.643-644.2001","volume":"45","author":"JM Sierra","year":"2001","unstructured":"Sierra, J. M. et al. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob. Agents Chemother. 45, 643\u2013644 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR20","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1128\/AAC.06315-11","volume":"56","author":"M Bielaszewska","year":"2012","unstructured":"Bielaszewska, M. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob. Agents Chemother. 56, 3277\u20133282 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/jcp.2009.071688","volume":"63","author":"ZD Jiang","year":"2010","unstructured":"Jiang, Z. D., DuPont, H. L., La Rocco, M. & Garey, K. W. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J. Clin. Pathol. 63, 355\u2013358 (2010).","journal-title":"J. Clin. Pathol."},{"key":"BFja2014106_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/MOG.0b013e328333dc8d","volume":"26","author":"HL Koo","year":"2010","unstructured":"Koo, H. L. & DuPont, H. L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 26, 17\u201325 (2010).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"BFja2014106_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijantimicag.2014.01.026","volume":"43","author":"KL Hopkins","year":"2014","unstructured":"Hopkins, K. L. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK. Int. J. Antimicrob. Agents 43, 431\u2013437 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFja2014106_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1128\/AAC.02163-12","volume":"57","author":"V Kothary","year":"2013","unstructured":"Kothary, V. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-\u03b2-naphthylamide-inhibitable efflux pumps. Antimicrob. Agents Chemother. 57, 811\u2013817 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFja2014106_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/mdr.2011.0010","volume":"18","author":"MJ Pons","year":"2012","unstructured":"Pons, M. J., Mensa, L., Gasc\u00f3n, J. & Ruiz, J. Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants. Microb. Drug. Resist. 18, 376\u2013379 (2012).","journal-title":"Microb. Drug. Resist."},{"key":"BFja2014106_CR26","doi-asserted-by":"publisher","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE 8, e60042 (2013).","journal-title":"PLoS ONE"},{"key":"BFja2014106_CR27","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","volume":"10","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis, G. N. et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815\u2013818 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFja2014106_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jhep.2013.01.003","volume":"58","author":"G Kakiyama","year":"2013","unstructured":"Kakiyama, G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58, 949\u2013955 (2013).","journal-title":"J. Hepatol."},{"key":"BFja2014106_CR29","doi-asserted-by":"crossref","unstructured":"Ahluwalia, V. et al. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gut-liver-brain axis. Metab. Brain Dis. doi:10.1007\/s11011-014-9507-6 (2014).","DOI":"10.1007\/s11011-014-9507-6"},{"key":"BFja2014106_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","volume":"146","author":"D Xu","year":"2014","unstructured":"Xu, D. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146, 484\u2013496 (2014).","journal-title":"Gastroenterology"},{"key":"BFja2014106_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1440-1746.2007.04933.x","volume":"22","author":"S Balzan","year":"2007","unstructured":"Balzan, S., de Almeida Quadros, C., de Cleva, R., Zilberstein, B. & Cecconello, I. Bacterial translocation: Overview of mechanisms and clinical impact. J. Gastroenterol. Hepatol. 22, 464\u2013471 (2007).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFja2014106_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","volume":"56","author":"Q Zhu","year":"2012","unstructured":"Zhu, Q. et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J. Hepatol. 56, 893\u2013899 (2012).","journal-title":"J. Hepatol."},{"key":"BFja2014106_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000068362","volume":"66","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci, S. et al. Inhibition of intestinal bacterial translocation with Rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66, 246\u2013256 (2002).","journal-title":"Digestion"},{"key":"BFja2014106_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","volume":"33","author":"J Cheng","year":"2012","unstructured":"Cheng, J., Shah, Y. M. & Gonzalez, F. J. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33, 323\u2013330 (2012).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFja2014106_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","volume":"668","author":"A Mencarelli","year":"2011","unstructured":"Mencarelli, A. et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur. J. Pharmacol. 668, 317\u2013324 (2011).","journal-title":"Eur. J. Pharmacol."},{"key":"BFja2014106_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1124\/jpet.110.170225","volume":"335","author":"J Cheng","year":"2010","unstructured":"Cheng, J. et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 335, 32\u201341 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFja2014106_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejps.2014.01.007","volume":"55","author":"J Terc","year":"2014","unstructured":"Terc, J., Hansen, A., Alston, L. & Hirota, S. A. Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis. Eur. J. Pharm. Sci. 55, 12\u201319 (2014).","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ja2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2014106","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ja2014106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:20:24Z","timestamp":1684416024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ja2014106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFja2014106"],"URL":"https:\/\/doi.org\/10.1038\/ja.2014.106","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]},"assertion":[{"value":"14 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}